-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

332. Antithrombotic Therapy: Poster II

Antithrombotic Therapy Program: Oral and Poster Abstracts
Type: Poster
Sunday, December 6, 2015: 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Khine Z Win, MD1,2, Nathan Wilson, PharmD3*, David D Stenehjem, PharmD4*, Natalee Tanner, PharmD5*, George M. Rodgers, MD, PhD6 and Jeffrey Gilreath, PharmD7*

1Department of Hematology/Oncology, University of New Mexico, Albuquerque, NM
2Department of Internal Medicine, University of Utah, Salt Lake city, UT
3University of Utah/ Huntsman Cancer Hospital, Salt Lake city, UT
4Department of Pharmacotherapy, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
5Department of Pharmacy, Banner MD Anderson cancer center, Gilbert, AZ
6Division of Hematology, University of Utah Hospital, Salt Lake City, UT
7Division of Hematology, University of Utah, Salt Lake City, UT

Martha L Louzada, BSc, MD, MSc1,2, Fatimah Al-Ani, MD, MRCP3*, Michael J. Kovacs, MD1, Lenicio Siqueira, BSc4* and Alejandro Lazo-Langner, MD, MSc2,5

1Department of Medicine, Division of Hematology, University of Western Ontario, London, ON, Canada
2Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada
3Department of Medicine, Division of Hematology, University of Western Ontario -London Health Sciences Centre, London, ON, Canada
4Department of Medicine, Division of Hematology, University of Western ontario, London, ON, Canada
5Department of Medicine, Division of Hematology, Western University - London Health Sciences Centre, London, ON, Canada

Fatimah Al-Ani, MD, MRCP1*, Martha L Louzada, BSc, MD, MSc2,3, Jose Maria Bastida Bermejo, PhD4* and Maria Victoria Mateos, MD, PhD4*

1Department of Medicine, Division of Hematology, University of Western Ontario -London Health Sciences Centre, London, ON, Canada
2Department of Medicine, Division of Hematology, University of Western Ontario, London, ON, Canada
3Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada
4Dpt of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain

Kenji Yokoyama, MD, PhD1, Naoki Ishizuka, PhD2*, Naomi Uemura, MD, PhD3*, Yuji Mizokami, MD, PhD4*, Hideyuki Hiraishi, MD, PhD5*, Tamio Teramoto, MD, PhD6*, Kazuyuki Shimada, MD, PhD7* and Yasuo Ikeda, MD, PhD8

1Department of Hematology/Oncology, Tokai University Hachioji Hospital, Hachioji, Japan
2Clinical Trial Department, Cancer Institute Hospital, Tokyo, Japan
3Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Kohnodai Hospital, Ichikawa, Japan
4Gastrointestinal Endoscopy Division, University of Tsukuba Hospital, Tsukuba, Japan
5Department of Gastroenterology, Dokkyo Medical University, Shimotsuga, Japan
6Teikyo Academic Research Center, Teikyo University, Tokyo, Japan
7Department of Cardiology, Shin-Oyama City Hospital, Oyama, Japan
8Graduate School of Advanced Science and Engineering,Waseda University, Tokyo, Japan

Lai Heng Lee, MBBS, MMed1, Chuen Wen Tan, MBBS2*, Wan Hui Wong1*, Foon yin Fung2*, Hwee Ling Koh3*, Yan Zhao4*, Mei Ching Kun2*, Xiao Mei Li2*, Heng Joo Ng, MRCP, MBBS, MMed1*, Seng Kok Ang2* and Yeh Ching Linn, MBBS, MRCP5*

1Haematology, Singapore General Hospital, Singapore, Singapore
2Singapore General Hospital, Singapore, Singapore
3National University of Singapore, Sinagpore, Singapore
4Nanyang Technological University, singapore, Singapore
5Haematology, Sinagpore General Hospital, Singapore, Singapore

Andrei Fagarasanu, MD, PhD1, Ghazi S Alotaibi, MD1*, Ramona Hrimiuc, MD1*, Agnes Y. Y. Lee, MD, MSc2,3 and Cynthia Wu, MD1

1Department of Medicine, University of Alberta, Edmonton, AB, Canada
2Department of Medicine, University of British Columbia, Vancouver, BC, Canada
3British Columbia Cancer Agency, Vancouver, BC, Canada

Srinath Sundararajan, MD1, Mugilan Poongkunran, MBBS2*, Chithra Poongkunran, MD3*, Arun Kannan, MD4* and Saravananan Balamuthusamy, MD, FASN5*

1Hematology-Oncology, University of Arizona, Tucson, AZ
2Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
3Internal Medicine, University of Arizona, Tucson, AZ
4Cardiology, University of Arizona, Tucson, AZ
5Tarrant Nephrology Associates, Fort Worth, TX

Aurelien Delluc, MD, PhD1*, Florence Hemon, MD1*, Fabrice Fouchard, MD2*, Cecile Tromeur, MD1*, Francis Couturaud, MD, PhD3*, Karine Lacut, MD, PhD1*, Dominique Mottier, PhD, MD1* and Gregoire Le Gal, MD, PhD4

1Brest university hospital, Brest, France
2Brest university, Brest, France
3Brest university hospital, CHU de Brest, France
4The Ottawa Hospital Research Institute, Ottawa, ON, Canada

Alexander T Cohen, MBBS MSc MD1*, Christopher Wallenhorst, MSc2*, Anja Katholing, MSc2*, Melissa Hamilton, MPH3*, Sreevalsa Unniachan, MBBS MPH3* and Carlos Martinez, MD MSc2*

1Haematological Medicine, Guy's and St Thomas' NHS Trust, King's College London, London, United Kingdom
2Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt, Germany
3Worldwide Health Economics and Outcomes Research, BMS, Princeton, NJ

Deepa Jayakody Arachchillage1,2*, Ian J Mackie1*, Maria Efthymiou1*, Andrew Chitolie1*, Beverley J Hunt3,4*, David Isenberg5,6*, Munther Khamashta7,8*, Samuel Machin1* and Hannah Cohen1,9*

1Haemostasis Research Unit, University College London, London, United Kingdom
2Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
3Haematology, Guy's and St Thomas NHS Foundation Trust, London, United Kingdom
4Haematology, King's College London, London, United Kingdom
5Centre for Rheumatology, University College London, London, United Kingdom
6University College London Hospitals NHS Foundation Trust, London, United Kingdom
7Rheumatology, Guy's and St Thomas Hospitals NHS Foundation Trust, London, United Kingdom
8Rheumatology, King's College London, London, United Kingdom
9Haematology, University College Hospitals NHS Foundation Trust, London, United Kingdom

Genmin Lu, PhD*, Joyce Lin, BS*, John T. Curnutte, MD, PhD and Pamela B. Conley, PhD

Portola Pharmaceuticals, Inc., South San Francisco, CA

Jennifer L Fan, MSIV1*, Laura E Roberts, MD2*, Mona D Shah, MD, MS3 and YoungNa J Lee-Kim, MD3

1Pediatrics, Baylor College of Medicine, Houston, TX
2Pediatrics, Baylor College of Medicine / Texas Children's Hospital, Houston, TX
3Texas Children's Cancer and Hematology Centers, Baylor College of Medicine / Texas Children's Hospital, Houston, TX

John K Abdou, MPharm1,2*, Jignesh P Patel, PhD1,2*, Bipin Vadher, MD2*, Alison Brown, BPharm2*, Lara N Roberts, MD2*, Raj K Patel, MD2*, Roopen Arya, PhD2* and Vivian Auyeung, PhD1*

1Institute of Pharmaceutical Sciences, King's College London, London, United Kingdom
2King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom

Kirill Lobastov, PhD1,2*, Iliya Schastlivtsev, PhD1,2*, Victor Barinov, PhD, MD1,2* and Valeriy Boyarintsev1*

1Clinical Hospital no.1 of the President's Administration of Russian Federation, Moscow, Russia
2Pirogovs Russian National Research Medical University, Moscow, Russia

Laura E Roberts, MD1*, Jennifer L Fan, MSIV2*, YoungNa J Lee-Kim, MD2,3 and Mona D Shah, MD, MS2,3

1Pediatrics, Baylor College of Medicine / Texas Children's Hospital, Houston, TX
2Pediatrics, Baylor College of Medicine, Houston, TX
3Texas Children's Cancer and Hematology Centers, Baylor College of Medicine / Texas Children's Hospital, Houston, TX

Jon Mabley, PhD1*, Greg Scutt, PhD2*, Kathryn Jane Lang, MRCP, MBBS3*, Jignesh P Patel, PhD4,5* and Roopen Arya, PhD5*

1School of Pharmacy and Biomolecular Sciences, Brighton, United Kingdom
2Brighton and Sussex Centre for Medicines Optimisation, School of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton, United Kingdom
3King's College Hospital NHS Foundation Trust, London, United Kingdom
4Institute of Pharmaceutical Sciences, King's College London, London, United Kingdom
5King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom

Shammim Haji, MPharm1*, Jignesh P Patel, PhD2,3*, Vivian Auyeung, PhD2*, Lara N Roberts, MD3*, Julia Czuprynska, MBBS3*, Raj K Patel, MD3* and Roopen Arya, PhD3*

1King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital, London, United Kingdom
2Institute of Pharmaceutical Sciences, King's College London, London, United Kingdom
3King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom

Brett L. Houston, MD1*, Dhruva J. Dwivedi, PhD.2,3*, Peter Grin3*, Michelle Kwong3*, Enrico Rullo3*, Momina A. Khan, MSc3*, Senay Asma, PhD.3*, Guillaume Pare, MD, MSc2,3*, Patricia C. Liaw, PhD.2,3, Ryan Zarychanski, MD, MSc4 and Alison E. Fox-Robichaud, MD, MSc2,3*

1Department of Medicine, University of Toronto, Toronto, ON, Canada
2Department of Medicine, McMaster University, Hamilton, ON, Canada
3Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
4Department of Medicine, Sections of Hematology / Medical Oncology and Critical Care, University of Manitoba, Winnipeg, MB, Canada

*signifies non-member of ASH